rare diseasesSobi’s dealmaker CEO exits for BioNTechGuido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue … more ➔
M&AAstraZeneca explores $400B combination with BMSAstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported. more ➔
clinical dataZEUS failure clouds future of Novo’s cardiovascular plansNovo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales. more ➔
licensingPharmanovia licenses China-approved PARP drug for up to €423.5MUK specialty pharma Pharmanovia has licensed senaparib, IMPACT Therapeutics’ oral PARP1/2 inhibitor, across 66 countries in a deal worth up to €423.5 million. more ➔
artificial intelligenceRelation deepens GSK alliance with $110M dealLondon-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to … more ➔
clinical dataSanofi axes two more inflammatory-disease drugsSanofi has discontinued development of itepekimab and balinatunfib after disappointing clinical results, ending ongoing programmes across respiratory and inflammatory diseases. more ➔
RegulatoryCHMP backs first CETP inhibitor after two decades of failureOn July 23, Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended the CETP inhibitor obicetrapib for approval after a string of big-name Phase 3 failures over the past two decades. … more ➔
financeGSK announces plan to axe UK Stevenage R&D hub, moving to CambridgeGSK has announced plans to shut its UK R&D headquarters in Stevenage, UK, moving operations north to a new site in Cambridge, while also announcing a company-wide programme to reduce annual costs by … more ➔
fundraisingPentixapharm raises €20.4M for Phase 3 diagnostic trialBerlin-based Pentixapharm Holding AG has raised about €20.4 million to fund a pivotal Phase 3 trial of its PET diagnostic PentixaFor and advance its CXCR4-targeted theranostics pipeline. more ➔
licensingChiesi retreats from Gossamer PAH programme after Phase 3 missItalian pharmaceutical group Chiesi has returned all development and commercial rights to seralutinib to Gossamer Bio, ending a pulmonary arterial hypertension partnership originally valued at up to … more ➔
